<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennie Clarke, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4537206"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) are variants of cutaneous lupus erythematosus (cutaneous LE) that may occur independently or as manifestations of systemic lupus erythematosus (SLE). DLE most commonly occurs on the head and is characterized by well-defined, inflammatory plaques that evolve into atrophic, disfiguring scars  (<a class="graphic graphic_picture graphicRef64844 graphicRef75833" href="/d/graphic/64844.html" rel="external">picture 1A-B</a>). SCLE typically presents with inflammatory, scaly papules or annular plaques on the neck, upper trunk, and arms  (<a class="graphic graphic_picture graphicRef66580 graphicRef55903" href="/d/graphic/66580.html" rel="external">picture 2A-B</a>).</p><p>Concern over the appearance of skin lesions leads most patients with DLE or SCLE to desire treatment  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). In particular, early treatment of DLE is essential to minimize scarring.</p><p>The initial approach to the treatment of patients with DLE or SCLE will be discussed here. The clinical manifestations of DLE and SCLE and the management of patients with refractory disease are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Discoid lupus erythematosus'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4677.html" rel="external">"Drug-induced lupus", section on 'Clinical spectrum of drug-induced lupus'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p></p><p>Risk for progression of DLE or SCLE to SLE is also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Association with systemic lupus erythematosus'</a>.)</p><p></p><p class="headingAnchor" id="H1495831"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The primary goal of treatment of DLE and SCLE is resolution of clinical signs of active disease (eg, scale, erythema, and induration). Scarring and dyspigmentation are complications of active disease that may persist despite resolution of active disease.</p><p>The management of patients with DLE and SCLE includes measures to achieve resolution of disease activity as well as interventions for associated conditions: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions for exacerbating factors (eg, sun exposure, medications)</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic treatment</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for progression to systemic lupus erythematosus (SLE)</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial support</strong></p><p></p><p>Most patients with DLE or SCLE respond to photoprotection combined with topical anti-inflammatory agents or systemic antimalarial drugs  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). Patients with disease refractory to these interventions may benefit from other treatments. (See <a class="local">'Interventions for exacerbating factors'</a> below and <a class="local">'Approach to pharmacologic therapy'</a> below and  <a class="medical medical_review" href="/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p>Both SCLE and DLE can occur in association with SLE, although co-occurrence of SCLE with SLE is more frequent. Monitoring for signs of SLE aids with identifying patients who require additional interventions for systemic disease. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Association with systemic lupus erythematosus'</a>.)</p><p>SCLE and DLE can negatively impact quality of life. Psychologic or psychiatric support may be helpful for addressing psychosocial factors associated with cutaneous lupus erythematosus (cutaneous LE). (See <a class="local">'Psychosocial support'</a> below.)</p><p class="headingAnchor" id="H5875549"><span class="h1">INTERVENTIONS FOR EXACERBATING FACTORS</span><span class="headingEndMark"> — </span>The elimination of exacerbating factors is an important component of long-term management. Key measures include:</p><p class="bulletIndent1"><span class="glyph">●</span>Strict photoprotection</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of photosensitizing medications (if feasible)</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for drug-induced disease in patients with SCLE</p><p></p><p class="headingAnchor" id="H4537221"><span class="h2">Photoprotection</span><span class="headingEndMark"> — </span>Patients with DLE or SCLE should engage in sun-protective measures on a daily basis, including the use of broad-spectrum sunscreens and sun-protective clothing [<a href="#rid1">1</a>]. Exposure to ultraviolet (UV) light and, in rare cases, visible light can be an exacerbating factor for cutaneous lupus erythematosus (cutaneous LE) [<a href="#rid1">1-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suggested measures</strong> – Given the lack of large-scale, comparative trials addressing the efficacy of different sunscreens in the management of cutaneous LE, patients generally should be advised to use broad-spectrum, water-resistant sunscreens with a sun protection factor (SPF) of at least 30. (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1">However, typical patient use of sunscreen often provides insufficient protection for the patient who is photosensitive. The importance of other sun-protective behaviors, including the use of sun-protective clothing, broad-brimmed hats, and sun avoidance (particularly during peak midday hours), must be emphasized. Specific products to reduce environmental UV exposure, such as UV-blocking films for car windows, are also available [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/6620.html" rel="external">"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection", section on 'Photoprotection'</a> and  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures", section on 'Photoprotective clothing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of ultraviolet light</strong> – In experimental settings, exposure to ultraviolet (UV) light has been shown to induce skin lesions in approximately 70 to 100 percent of patients with SCLE [<a href="#rid10">10-13</a>] and approximately 64 percent of patients with DLE [<a href="#rid14">14</a>]. The latency period between sun exposure and the development of photo-induced skin lesions can last from several days to three weeks [<a href="#rid15">15</a>]. Thus, some patients may fail to associate exacerbations of skin lesions with photosensitivity.</p><p></p><p class="bulletIndent1">Few studies have addressed the efficacy of sunscreen in preventing the development of skin lesions. The following data support sunscreen use in this population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a company-sponsored, randomized, intraindividual trial of 25 patients with cutaneous LE (17 with lupus erythematosus tumidus, five with DLE, and three with SCLE), experimental ultraviolet A (UVA) or ultraviolet B (UVB) irradiation failed to induce skin lesions in all sites treated with an SPF 60 sunscreen containing ethylhexyl methoxycinnamate, titanium dioxide, <a class="drug drug_general" data-topicid="10326" href="/d/drug information/10326.html" rel="external">zinc oxide</a>, and methylene bis-benzotriazolyl tetramethylbutylphenol [<a href="#rid16">16</a>]. In contrast, skin lesions consistent with cutaneous LE developed in untreated or vehicle-treated sites in 16 patients (64 percent) and 14 patients (56 percent), respectively. (See  <a class="medical medical_review" href="/d/html/6620.html" rel="external">"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection", section on 'Photoprotection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An intraindividual study of 11 patients with DLE or SCLE compared the ability of three different broad-spectrum sunscreens to protect against the development of skin lesions after exposure to UVA and UVB [<a href="#rid17">17</a>]. All three sunscreens had protective effects. The most protective sunscreen prevented the development of skin lesions in all patients and had an SPF of 60. This sunscreen contained octocrylene, avobenzone, ecamsule, drometrizole trisiloxane, and titanium dioxide.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study found that an SPF 30 broad-spectrum sunscreen containing avobenzone, octocrylene, ethylhexyl triazone, drometrizole trisiloxane, and titanium dioxide was highly effective in preventing new lesions following irradiation with UVA and UVB in 49 out of 51 patients with cutaneous LE (primarily DLE or lupus tumidus) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An eight-week, open-label study, in which subjects with DLE and SCLE were instructed to apply a broad-spectrum sunscreen with an SPF greater than 15 that contained avobenzone and padimate O, demonstrated that daily use of this sunscreen led to a decrease in disease severity [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H4537235"><span class="h2">Avoidance of exacerbating drugs</span><span class="headingEndMark"> — </span>Drug-induced SCLE presents with cutaneous and serologic findings similar to idiopathic disease. Medications that are associated with drug-induced SCLE should be discontinued or avoided when possible in patients with SCLE  (<a class="graphic graphic_table graphicRef62265" href="/d/graphic/62265.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Drug-induced subacute cutaneous lupus erythematosus'</a>.)</p><p>Withdrawal of the culprit agent often leads to resolution of the skin disease. However, many patients have persistently detectable autoantibodies (SSA/Ro antibodies or SSB/La antibodies), and a minority have persistent skin disease [<a href="#rid20">20</a>].</p><p>In addition, medications that are known to cause photosensitivity may exacerbate symptoms in patients with idiopathic DLE or SCLE and should be avoided [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Photosensitivity due to exogenous agents'</a>.)</p><p class="headingAnchor" id="H4196554484"><span class="h1">APPROACH TO PHARMACOLOGIC THERAPY</span><span class="headingEndMark"> — </span>In addition to photoprotection and avoidance of other exacerbating factors, most individuals with DLE or SCLE require pharmacologic therapy to control active disease. The extent and severity of skin involvement influences the approach to initial treatment  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). (See <a class="local">'Limited disease'</a> below and <a class="local">'Extensive disease or disease resistant to local therapy'</a> below and <a class="local">'Aggressive disease'</a> below.)</p><p class="headingAnchor" id="H452520223"><span class="h2">Limited disease</span><span class="headingEndMark"> — </span>Limited disease may be considered disease that is unlikely to cause disfigurement (eg, scarring or dyspigmentation on the face) and consists of a degree of skin involvement for which daily topical therapy is often manageable (eg, a limited amount of skin in body site[s] the patient can easily reach).</p><p class="headingAnchor" id="H2949731258"><span class="h3">Approach</span><span class="headingEndMark"> — </span>Patients with DLE or SCLE involving a limited body surface area can often be treated with local therapy. Topical corticosteroids are an appropriate first-line therapy  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) [<a href="#rid21">21,22</a>]. Topical calcineurin inhibitors (<a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a>) and intralesional corticosteroid injections are alternative local therapies.</p><p>Initial treatment with topical corticosteroids is often preferred over topical calcineurin inhibitors because of the higher cost of topical calcineurin inhibitors compared with some topical corticosteroids. In addition, in DLE, some studies suggest greater efficacy of super high-potency topical corticosteroids compared with topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. (See <a class="local">'Topical calcineurin inhibitors'</a> below.)</p><p>However, the lack of risk for corticosteroid-induced skin atrophy is a favorable characteristic of topical calcineurin inhibitors, particularly for patients requiring long-term topical therapy on sites at greatest risk for cutaneous atrophy (eg, face or intertriginous areas). In accordance, some authors have suggested using high-potency topical corticosteroids for the initial treatment of severe, acute flares of DLE and SCLE, followed by the use of a topical calcineurin inhibitor once control of the acute flare has been achieved [<a href="#rid23">23</a>]. (See <a class="local">'Topical calcineurin inhibitors'</a> below.)</p><p>Intralesional corticosteroid injections are often reserved for patients who fail topical therapy, given the discomfort associated with multiple injections. However, some patients may prefer the intermittent nature of interlesional therapy over daily application of topical corticosteroid therapy. Intralesional therapy is most applicable for the treatment of a few small areas of skin involvement. (See <a class="local">'Intralesional corticosteroids'</a> below.)</p><p>Patients with limited disease that responds insufficiently to one or more local therapies are candidates for systemic antimalarial therapy. (See <a class="local">'Extensive disease or disease resistant to local therapy'</a> below.)</p><p class="headingAnchor" id="H4537257"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>Topical corticosteroids are appropriate first-line therapies for patients with limited DLE or SCLE, and some patients with limited disease can be adequately managed with photoprotection and topical corticosteroids alone  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) [<a href="#rid21">21,24-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The approach to topical corticosteroid therapy differs slightly for DLE and SCLE:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Discoid lupus erythematosus</strong> – We suggest twice-daily application of a super high-potency or high-potency topical corticosteroid (groups 1 or 2), such as <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate, as first-line therapy for acute flares of DLE  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 2</a>) [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent2">Although the use of high-potency topical corticosteroids on the face is typically avoided, they are often used for the treatment of facial DLE because of the importance of disease control for the minimization of scarring. (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subacute cutaneous lupus erythematosus</strong> – We suggest twice-daily application of a super high-potency to medium-potency topical corticosteroid (class 1 to 4) as initial therapy for acute flares of SCLE  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Improvement in DLE and SCLE with topical corticosteroids is typically noted within days to two weeks of the initiation of therapy. If an acute flare of DLE or SCLE has not responded to a high-potency topical corticosteroid after two to four weeks, we proceed to an alternative therapy  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">For patients who exhibit continuing improvement with topical corticosteroid therapy but have residual disease activity after four weeks, topical corticosteroid therapy can be continued at the lowest potency and frequency that supports continued improvement provided there are no signs of corticosteroid-induced cutaneous atrophy. When all signs of disease activity (eg, scale, erythema, induration) are absent, treatment can be discontinued. Scarring and dyspigmentation will be unaffected by continued treatment.</p><p></p><p class="bulletIndent1">Data on topical corticosteroid maintenance regimens are lacking. For patients who achieve resolution of disease activity with topical corticosteroids but experience rapid recurrence of disease activity upon the withdrawal of topical corticosteroid therapy, we typically initiate a long-term maintenance regimen with a topical corticosteroid or topical calcineurin inhibitor. We use the lowest potency topical corticosteroid and lowest frequency of application that maintains improvement:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For maintenance therapy on the face, we typically use up to twice-daily application of a low-potency topical corticosteroid (groups 6 or 7), such as <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 1% or 2.5%, as long as evidence of disease activity persists (erythema and scale)  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For maintenance therapy on the trunk, extremities, or scalp, we typically use up to twice-daily application of medium-potency to high-potency topical corticosteroids (groups 2 to 4), such as <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide 0.1% cream or <a class="drug drug_general" data-topicid="8460" href="/d/drug information/8460.html" rel="external">fluocinonide</a> 0.05% cream, as long as evidence of disease activity persists.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – High-quality studies on the efficacy of topical corticosteroids for DLE and SCLE are limited, and the use of topical corticosteroids for DLE as first-line agents is primarily based upon documentation of successful treatment from early case reports and studies [<a href="#rid24">24-27</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a double-blind trial (n = 20) in which two lesions on each patient were treated with either <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a> acetonide 0.025% ointment (a medium-potency topical corticosteroid) three times daily or a vehicle control, fluocinolone was superior to the vehicle for the treatment of DLE [<a href="#rid25">25</a>]. The same authors reported efficacy of fluocinolone acetonide 0.025% ointment in a series of 28 patients. After 18 days, 14 patients showed complete or almost complete regression of skin lesions, and only two patients failed to improve.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The use of very low-potency agents for DLE is discouraged by the results of a randomized trial (n = 78) in which application of <a class="drug drug_general" data-topicid="8460" href="/d/drug information/8460.html" rel="external">fluocinonide</a> 0.05% cream was superior to <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 1% cream for the treatment of DLE (27 versus 10 percent, respectively, achieved complete clearance or excellent improvement after six weeks of therapy) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">Although there are no high-quality studies of the efficacy of topical corticosteroids for the treatment of SCLE, our experiences and the clinical experiences of others suggest efficacy of this therapy [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Cutaneous atrophy is a potential side effect of the long-term use of topical corticosteroids, particularly higher-potency agents. Patients should be advised to limit the application of topical corticosteroids to the involved skin only and should be followed closely for the development of atrophy. Adverse effects related to systemic absorption may also occur with topical corticosteroid use, especially when treating large areas of involvement. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H4537265"><span class="h3">Topical calcineurin inhibitors</span><span class="headingEndMark"> — </span>Topical calcineurin inhibitors are alternative anti-inflammatory drugs for the treatment of DLE or SCLE  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) [<a href="#rid23">23,30-32</a>].</p><p>We typically use topical calcineurin inhibitors for patients who have failed treatment with topical corticosteroids or for long-term therapy for thin lesions in atrophy-prone areas, such as the face. Topical calcineurin inhibitors may be slower acting than topical corticosteroids but do not induce cutaneous atrophy. Concerns have also been raised over the ability of these agents to penetrate thick, hypertrophic lesions of DLE [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Topical calcineurin inhibitors used for DLE and SCLE include <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.03% or 0.1% ointment. We typically treat with the 0.1% concentration of tacrolimus. Topical calcineurin inhibitors are applied to the affected areas twice daily.</p><p></p><p class="bulletIndent1">In general, improvement in symptoms can be expected within the first four weeks of treatment, and complete clearance of thin patches or plaques may occur within two months [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of topical calcineurin inhibitors for cutaneous lupus erythematosus (cutaneous LE) has been evaluated in a few randomized trials with limited numbers of patients and variable results [<a href="#rid33">33-36</a>]. A 12-week, vehicle-controlled trial of topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment in 30 patients with various forms of cutaneous LE refractory to topical corticosteroid therapy found limited evidence for the efficacy of tacrolimus specifically for DLE and SCLE [<a href="#rid33">33</a>]. In the trial, which included 14 patients with DLE and 4 patients with SCLE, improvement in lesion severity was noted in tacrolimus-treated patients, but the degree of improvement was not superior to the improvement detected in vehicle-treated patients.</p><p></p><p class="bulletIndent1">Although these findings raise doubt about the efficacy of topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> for DLE and SCLE, the number of patients with DLE and SCLE was small, the study included patients who were failing to respond sufficiently to systemic therapies, and encouragement of patient sunscreen use may have contributed to lesion regression. In contrast, two small, randomized trials comparing topical tacrolimus and <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> with topical corticosteroids, which are generally accepted to be effective for cutaneous LE, suggest benefit from calcineurin inhibitors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an eight-week trial in which 10 patients with DLE were treated with either twice-daily application of <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream or twice-daily application of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> 17-valerate 0.1% cream (a medium-potency topical corticosteroid), there was no significant difference in efficacy or adverse effects between the two agents [<a href="#rid34">34</a>]. The mean clinical severity scores in the trial decreased by 86 and 73 percent, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another trial investigating the efficacy of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment versus <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05% ointment (a superpotent topical corticosteroid) for various forms of cutaneous LE reported similar efficacy but found an increased risk for the development of telangiectasias in subjects treated with clobetasol propionate [<a href="#rid35">35</a>]. The efficacy data from this trial may be less applicable since only 5 out of 20 patients in the trial had DLE or SCLE.</p><p></p><p class="bulletIndent1">Other studies suggest greater efficacy of super high-potency topical corticosteroids in DLE:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a split-body, randomized trial in which 21 patients with DLE applied <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment to one randomly assigned side of the body and <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05% ointment to the contralateral side for six weeks, both treatments were associated with reductions in disease activity scores, but clobetasol demonstrated a greater median reduction [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A nonrandomized, comparative study (n = 40) compared the efficacy of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% with <a class="drug drug_general" data-topicid="8514" href="/d/drug information/8514.html" rel="external">halobetasol</a> propionate 0.05% (a super high-potency topical corticosteroid) in patients receiving <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> for DLE. After eight weeks, there were statistically significant reductions in the erythema, scale/hypertrophy, and total disease activity scores in both groups but a greater reduction in the scale/hypertrophy scores in the halobetasol propionate group [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">Uncontrolled studies also suggest efficacy of topical calcineurin inhibitors in small numbers of patients [<a href="#rid38">38-40</a>].</p><p></p><p class="bulletIndent1">Simultaneous therapy with topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate has also been used with success in cutaneous LE [<a href="#rid41">41,42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Both <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> are generally well tolerated. The most common side effect is a transient burning or stinging sensation after application that typically resolves within the first one to two weeks of use.</p><p></p><p class="bulletIndent1">In 2006, the US Food and Drug Administration (FDA) placed a black box warning on topical calcineurin inhibitors due to a concern for their potential carcinogenesis based on animal studies. However, a causal relationship has not been established. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Topical calcineurin inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H423083"><span class="h3">Intralesional corticosteroids</span><span class="headingEndMark"> — </span>Intralesional corticosteroid injections are an alternative local therapy  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). In addition, patients with focal lesions that do not respond to topical corticosteroids or topical calcineurin inhibitors can be treated with intralesional corticosteroid injections:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">Triamcinolone</a> acetonide in concentrations ranging from 3 to 5 mg/mL is typically used. A small-diameter needle (ideally 30 gauge) is used to inject approximately 0.1 mL of the medication into the target site. Multiple injections within a single lesion should be placed approximately 1 cm apart. For patients who cannot tolerate the pain associated with injection, a topical anesthetic can be applied prior to the procedure. (See  <a class="medical medical_review" href="/d/html/5568.html" rel="external">"Intralesional corticosteroid injection"</a>.)</p><p></p><p class="bulletIndent1">Injections are repeated every three to four weeks until erythema and scale are no longer present. If no response has occurred after two to three injections, alternative treatment should be considered.</p><p></p><p class="bulletIndent1">Some patients, most often those with SCLE, have too many lesions to treat successfully with intralesional corticosteroids alone due to the large number of injections that would be required [<a href="#rid9">9</a>]. In the author's clinical practice, most patients are treated with less than 10 mg of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide per session.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Although this modality has been utilized by multiple experts for DLE and SCLE [<a href="#rid9">9,11,43-48</a>], there are no high-quality studies of intralesional corticosteroids for these indications. In one series of patients with DLE, a clinical response characterized as very good or excellent was achieved by 26 out of 40 patients treated with 3 or 4 mg/mL of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – As with topical corticosteroids, cutaneous atrophy and pigmentary changes can occur with intralesional administration of corticosteroids. Periocular injections should be approached with caution, as central retinal artery occlusion leading to visual impairment is a potential adverse event [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Systemic absorption also occurs with intralesional administration. In addition to the practical limitations of numerous injections, the risk of systemic side effects limits the use of this modality to disease involving small amounts of skin surface area. (See  <a class="medical medical_review" href="/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p></p><p class="headingAnchor" id="H3755999722"><span class="h2">Extensive disease or disease resistant to local therapy</span><span class="headingEndMark"> — </span>Extensive disease may be considered a degree of skin involvement for which daily topical therapy would be challenging for many patients.</p><p>Patients with aggressive, rapidly progressing disease may benefit from the addition of systemic corticosteroid therapy  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). (See <a class="local">'Aggressive disease'</a> below.)</p><p class="headingAnchor" id="H1451279833"><span class="h3">Approach</span><span class="headingEndMark"> — </span>When local treatment is impractical due to the presence of extensive disease or limited disease fails to respond adequately to local treatment, systemic antimalarial therapy is our preferred treatment  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) [<a href="#rid21">21,22</a>].</p><p>Local therapies (topical corticosteroids, topical calcineurin inhibitors, or intralesional corticosteroids) may be beneficial as adjunctive therapy. In particular, topical corticosteroids are useful as a bridge therapy during the first few weeks of treatment while awaiting the onset of slower-acting systemic agents.</p><p><a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> is the most common agent used in the treatment of cutaneous LE and our preferred first-line treatment. Other antimalarial drugs are generally reserved for patients with inadequate responses to hydroxychloroquine. (See <a class="local">'Antimalarial drugs'</a> below.)</p><p>Other immunosuppressive or immunomodulatory therapies may be tried if antimalarial therapy fails or cannot be tolerated. (See  <a class="medical medical_review" href="/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p class="headingAnchor" id="H1493864"><span class="h3">Antimalarial drugs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> and <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> are the primary antimalarial agents that are utilized in the treatment of DLE and SCLE  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). Hydroxychloroquine and chloroquine are 4-aminoquinoline antimalarial compounds that have very similar pharmacokinetics, action, and metabolism [<a href="#rid50">50,51</a>] (see  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Treatment of DLE or SCLE with antimalarial drugs is most often initiated with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> because it is generally accepted to have the best side effect profile. <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">Chloroquine</a> has a greater risk of retinal toxicity and gastrointestinal intolerance, and quinacrine is more likely to cause hematologic adverse effects [<a href="#rid52">52</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimen</strong> – We treat most adult patients with a starting dose of <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> of 200 mg/day, followed by an increase to 200 mg twice daily after one to two weeks if the drug is well tolerated. Starting with the once-daily dose may reduce gastrointestinal side effects. The dose of hydroxychloroquine should not exceed 5 mg/kg of real body weight per day to minimize risk for retinopathy [<a href="#rid53">53</a>]. The safety of hydroxychloroquine in pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Hydroxychloroquine'</a>.)</p><p></p><p class="bulletIndent2">Because there is a delay in the onset of action of antimalarials, six to eight weeks should elapse before efficacy is assessed. Once satisfactory improvement is attained with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, the dose can be decreased to 200 mg/day for maintenance therapy [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2">Many patients with purely cutaneous disease can discontinue their antimalarials during winter months, when photoexacerbation is less of a problem.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with insufficient responses to </strong><strong>hydroxychloroquine</strong> – If <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> therapy does not result in resolution of disease activity, the antimalarial regimen can be adjusted, or therapies for refractory disease can be utilized:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">Chloroquine</a> may be substituted for <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> because there is a small subset of patients who respond preferentially to this drug [<a href="#rid9">9,54</a>]. Limiting the chloroquine dose to less than or equal to 2.3 mg/kg of real body weight per day is suggested to minimize risk for retinopathy [<a href="#rid53">53</a>]. Chloroquine and hydroxychloroquine should <strong>not</strong> be used together because of an unacceptably high risk of retinal toxicity. (See  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Ocular effects'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The selection of therapy for refractory disease is reviewed separately. (See  <a class="medical medical_review" href="/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p></p><p class="bulletIndent2">Some authors suggest the addition of quinacrine (100 mg per day) to <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> as a next step when monotherapy with hydroxychloroquine is unsuccessful [<a href="#rid55">55-58</a>]. However, in some countries (including the United States), quinacrine can only be obtained through specialty compounding pharmacies, and shortages and manufacturing difficulties have made it difficult to obtain. Quinacrine also lacks regulatory approval for any medical indication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Many patients with cutaneous LE will respond to monotherapy with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid46">46,54,59,60</a>]. In a randomized trial comparing treatment of cutaneous LE with hydroxychloroquine with treatment with <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> (n = 58), 50 percent of patients with DLE or SCLE treated with 400 mg/day of hydroxychloroquine and 46 percent of patients treated with acitretin achieved complete clearance or marked improvement after eight weeks of therapy [<a href="#rid59">59</a>]. Treatment success was also evident in a series of 34 patients with DLE [<a href="#rid46">46</a>]. Twenty-four patients (70 percent) achieved a good to excellent response with hydroxychloroquine (200 to 400 mg/day) for at least six weeks.</p><p></p><p class="bulletIndent1">Although the limited availability of quinacrine is often prohibitive, results from the following studies suggest that combination therapy with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> and quinacrine may be associated with improved response:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective study of patients with various forms of cutaneous LE who failed to respond to <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> alone (19 patients with DLE and 10 with SCLE), combination therapy led to an 84 percent response rate and a statistically significant improvement in disease activity among the subjects with DLE [<a href="#rid55">55</a>]. Among the patients with SCLE, 60 percent showed improvement on clinical examination. However, the decrease in disease activity was not statistically significant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective cohort study composed of patients with various forms of cutaneous LE found that combination therapy with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> and quinacrine significantly reduced disease activity in patients who had previously failed hydroxychloroquine [<a href="#rid54">54</a>]. Ten out of 15 patients (67 percent) improved with combination therapy. Due to the small number of patients, subtype-specific response rates could not be reliably assessed.</p><p></p><p class="bulletIndent1">In a prospective study of 300 patients with cutaneous LE, serum levels of <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> correlated with treatment efficacy, suggesting that laboratory testing may be of value for distinguishing true resistance to hydroxychloroquine from factors such as poor patient compliance and inadequate drug dosing [<a href="#rid61">61</a>]. Further studies are necessary to determine the role of quantitative drug levels in the identification of antimalarial-resistant DLE and SCLE. The availability of the test is limited.</p><p></p><p class="bulletIndent1">The impact of smoking on the effectiveness of antimalarial drugs is unclear. (See <a class="local">'Smoking cessation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Antimalarial drugs are generally well tolerated. Adverse effects include gastrointestinal distress; ocular toxicity (<a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> and <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>); and neuropsychiatric, neuromuscular, or hematologic abnormalities. Patients receiving hydroxychloroquine or chloroquine therapy should receive a baseline ophthalmologic examination and periodic ophthalmologic examinations thereafter. (See  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Routine eye examinations'</a>.)</p><p></p><p class="bulletIndent1">Cutaneous alterations may also occur with antimalarial therapy, including blue-gray pigmentation on the shins, face, or palate, as well as bleaching of lightly pigmented hair. In addition, diffuse, yellow discoloration of the skin, sclera, and body secretions is a frequent side effect of quinacrine therapy.</p><p></p><p class="headingAnchor" id="H2466923696"><span class="h2">Aggressive disease</span><span class="headingEndMark"> — </span>Occasionally, patients present with disease that is rapidly progressing or associated with risk for worsening scarring or cosmetically significant pigmentary alteration (eg, progressive DLE on the face)  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>). Such patients should proceed directly to oral antimalarial therapy rather than topical monotherapy. In addition, we suggest a short course of systemic corticosteroid therapy [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H3718677379"><span class="h3">Systemic corticosteroids</span><span class="headingEndMark"> — </span>The goal of systemic corticosteroid therapy is to attain rapid control of disease while awaiting the onset of oral antimalarial drugs. Systemic corticosteroids should not be used as primary therapy because of a risk for severe adverse effects with long-term therapy. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Typical dosing for systemic corticosteroid therapy for adults consists of 0.5 to 1 mg/kg per day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> administered for two to four weeks, with the aim of subsequent tapering and discontinuation [<a href="#rid21">21</a>].</p><p>A cohort study that assessed the efficacy of multiple treatments in 1002 patients with various forms of cutaneous LE suggests benefit of systemic corticosteroids [<a href="#rid62">62</a>]. Benefit was reported in greater than 90 percent of patients with DLE (n = 128) or SCLE (n = 99) treated with systemic corticosteroids.</p><p class="headingAnchor" id="H1213235123"><span class="h1">MONITORING FOR PROGRESSION TO SYSTEMIC LUPUS ERYTHEMATOSUS</span><span class="headingEndMark"> — </span>Patients with SCLE and DLE are at risk for the coexistence or future development of systemic lupus erythematosus (SLE). Risk varies with the clinical presentation, with risk in patients with SCLE higher than in patients with limited or generalized DLE. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Association with systemic lupus erythematosus'</a>.)</p><p>Patients should be evaluated for SLE at the time of diagnosis. This typically includes a clinical history with a particular focus on a rheumatologic review of systems, a physical examination, and select laboratory studies. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Diagnostic approach'</a>.)</p><p>Although there is general agreement that patients diagnosed with SCLE or DLE should receive long-term monitoring for the development of SLE, approaches to subsequent evaluation vary. We typically perform at least the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Review of systems at each follow-up visit</p><p class="bulletIndent1"><span class="glyph">●</span>Annual full history and physical examination</p><p class="bulletIndent1"><span class="glyph">●</span>Annual complete blood count with differential</p><p class="bulletIndent1"><span class="glyph">●</span>Annual urinalysis</p><p></p><p>Patients who exhibit signs or symptoms suggestive of SLE should receive the standard diagnostic work-up of other patients with suspected SLE. Repetition of an antinuclear antibody (ANA) titer is not indicated for patients who had a positive ANA at the time of the cutaneous lupus erythematosus (cutaneous LE) diagnosis. (See  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H110863249"><span class="h1">PSYCHOSOCIAL SUPPORT</span><span class="headingEndMark"> — </span>Cutaneous lupus erythematosus (cutaneous LE) has been associated with negative effects on quality of life, increased risk for depression, and other psychosocial challenges [<a href="#rid63">63,64</a>]. A Danish, cross-sectional study that included 1424 patients with cutaneous LE, 2065 patients with systemic lupus erythematosus (SLE), and approximately 35,000 matched controls found an adjusted hazard ratio of depression of 2.07 (95% CI 1.55-2.75) for patients with cutaneous LE [<a href="#rid63">63</a>]. In a separate study that included 49 patients seen at an autoimmune skin disease clinic for cutaneous LE, 17 patients (35 percent) met criteria for depression and/or anxiety, with need for intervention based upon scores on validated questionnaires [<a href="#rid65">65</a>].</p><p>Awareness of the association of cutaneous LE with psychosocial effects and psychiatric disorders is helpful for identifying patients who may benefit from professional evaluation or intervention. Examples of additional resources for social support and information that patients may find helpful include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.lupus.org%2F&amp;token=6adX8eSyuMhIqrQHY4S4L0EXJsotA8yFErJfPOu6WkY%3D&amp;TOPIC_ID=13772" target="_blank">Lupus Foundation of America</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.lupuscanada.org%2F&amp;token=6adX8eSyuMhIqrQHY4S4L5OYCSKt6byPocF0vDM5qv1M2lciGhLW%2Fypn9wBQ5FDd&amp;TOPIC_ID=13772" target="_blank">Lupus Canada</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.lupusuk.org.uk%2F&amp;token=6adX8eSyuMhIqrQHY4S4LzgKZQ9TsHj3AmXIonU7Zs2eOWnVsUyqYsCy865S3nN0&amp;TOPIC_ID=13772" target="_blank">Lupus UK</a></p><p></p><p class="headingAnchor" id="H3372472826"><span class="h1">OTHER INTERVENTIONS</span></p><p class="headingAnchor" id="H2245978973"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>The impact of smoking cessation on the treatment of DLE and SCLE is unclear:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on disease</strong> – Smoking has been associated with the development of cutaneous lupus erythematosus (cutaneous LE) and may contribute to the development of more severe disease [<a href="#rid66">66-70</a>]. In a case-control study of 108 patients with cutaneous LE (majority with DLE or SCLE), patients with cutaneous LE were more likely to be smokers than matched controls (odds ratio [OR] 2.77, 95% CI 1.63-4.76) [<a href="#rid70">70</a>]. Smoking preceded the onset of symptoms in 91 percent of the affected smokers. Additional studies are necessary to determine the effect of smoking cessation on disease activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on antimalarial therapy</strong> – There is uncertainty about the impact of smoking on the efficacy of antimalarial therapy for DLE and SCLE. A meta-analysis of observational studies that assessed the impact of smoking on the response of cutaneous LE to antimalarial drugs found a twofold reduction in the likelihood of clinical improvement among smokers compared with nonsmokers (pooled OR 0.53, 95% CI 0.29-0.98) [<a href="#rid71">71</a>]. This meta-analysis, however, did not limit the analysis to studies including only patients with DLE or SCLE.</p><p></p><p class="bulletIndent1">Moreover, no studies have identified smoking as an independent risk factor for antimalarial failure in patients with cutaneous LE. One large, retrospective cohort study failed to demonstrate reduced antimalarial efficacy among smokers with DLE [<a href="#rid72">72</a>], and a prospective cohort study has shown increased responsiveness of cutaneous LE to antimalarial therapy among smokers with mild disease as compared with nonsmokers with mild disease [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">Additional research will be useful for clarifying the impact of smoking on antimalarial therapy. It is possible that factors such as increased disease severity among subjects who smoke and nonadherence to antimalarial therapy in smokers may be responsible for antimalarial failure in some patients who smoke. If smoking has a negative effect on antimalarial therapy, nicotine interference with uptake of drug into cell lysosomes or the acceleration of the metabolic clearance of these medications is a potential mechanism [<a href="#rid74">74</a>]. It is unclear whether the use of nicotine substitutes (eg, chewing gums, patches, or inhalers) could have a similar effect, so when possible, smoking cessation without the use of these aids is preferable. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="headingAnchor" id="H159427376"><span class="h2">Assessment for vitamin D deficiency</span><span class="headingEndMark"> — </span>Vitamin D deficiency may have deleterious effects on multiple organ systems. In addition to diet as a source of vitamin D, vitamin D is synthesized in the skin after sun exposure. Thus, the possibility of vitamin D deficiency should be considered in patients with cutaneous LE, particularly those who engage in strict sun-protective measures [<a href="#rid75">75-77</a>]. Due to the potential adverse effects of vitamin D deficiency, we typically test patients with cutaneous LE annually for this disorder. (See  <a class="medical medical_review" href="/d/html/13915.html" rel="external">"Vitamin D and extraskeletal health"</a> and  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p>In a study of 52 patients with cutaneous LE, 65 percent exhibited 25-hydroxyvitamin D levels of less than 75 nmol/L (30 ng/mL), a level that is often defined as vitamin D insufficiency [<a href="#rid75">75</a>]. Vitamin D levels were significantly lower in subjects who engaged in daily sunscreen use or sun avoidance compared with those who did not.</p><p>Low levels of vitamin D may play a role in autoimmunity [<a href="#rid78">78</a>], and it is unknown whether low levels of vitamin D increase the risk for cutaneous LE or augment the severity of the disease. One small, uncontrolled study reported no change in disease activity with vitamin D supplementation in patients with cutaneous LE and vitamin D deficiency [<a href="#rid79">79</a>]. There are no high-quality studies investigating the effect of vitamin D supplementation on the prevention or treatment of cutaneous LE. (See  <a class="medical medical_review" href="/d/html/13915.html" rel="external">"Vitamin D and extraskeletal health", section on 'Immune system'</a>.)</p><p class="headingAnchor" id="H3674285423"><span class="h2">Topical retinoids</span><span class="headingEndMark"> — </span>Systemic retinoids have been used in the treatment of refractory cutaneous LE, but evidence to support the efficacy of topical retinoids for this indication is limited to case reports describing the use of tretinoin 0.05% cream and <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a> 0.05% gel for hypertrophic lesions of DLE [<a href="#rid80">80,81</a>]. (See  <a class="medical medical_review" href="/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy", section on 'Oral retinoids'</a>.)</p><p>The basis for the use of topical retinoids in cutaneous LE is the ability of these drugs to decrease inflammation and slow abnormal differentiation and hyperproliferation of keratinocytes. We do not routinely use topical retinoids in the management of cutaneous LE.</p><p>Topical retinoids are not recommended in pregnancy. The most common side effect of topical retinoids is cutaneous irritation.</p><p class="headingAnchor" id="H1511876540"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119580.html" rel="external">"Society guideline links: Cutaneous lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H11842065"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87700.html" rel="external">"Patient education: Discoid lupus (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4537286"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for treatment</strong> – Discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) may occur independently or in association with systemic lupus erythematosus (SLE). Concern over the appearance of skin lesions drives many patients to seek therapy. Treatment of DLE early in the course of the disease is essential to minimize the development of scarring. (See <a class="local">'Introduction'</a> above and <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of management</strong> – Key components of the management of DLE and SCLE include interventions for exacerbating factors, pharmacologic therapy, monitoring for SLE, and psychologic support. (See <a class="local">'Overview'</a> above and <a class="local">'Monitoring for progression to systemic lupus erythematosus'</a> above and <a class="local">'Psychosocial support'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions for exacerbating factors</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Photoprotection</strong> – Sun-protective measures are an important component of the management of DLE and SCLE. Patients should use broad-spectrum sunscreen with a sun protection factor (SPF) ≥30 on a daily basis. Other sun-protective measures, such as hats, protective clothing, and sun avoidance, are an integral part of the treatment regimen. (See <a class="local">'Photoprotection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication review</strong> – Certain medications can incite or exacerbate cutaneous lupus erythematosus (cutaneous LE)  (<a class="graphic graphic_table graphicRef62265" href="/d/graphic/62265.html" rel="external">table 1</a>). In patients with SCLE, medications that can induce the disorder should be identified and discontinued. Medications that increase photosensitivity also should be avoided or discontinued in patients with cutaneous LE. (See <a class="local">'Avoidance of exacerbating drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial pharmacologic therapy</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited disease</strong> – For the initial treatment of most patients with<strong> </strong>limited DLE or SCLE, we suggest local therapy rather than systemic therapy  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">For most patients, we suggest initial treatment with topical corticosteroids rather than topical calcineurin inhibitors or intralesional corticosteroid injections (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical calcineurin inhibitors are more expensive than some topical corticosteroids, and limited data suggest greater efficacy of super high-potency topical corticosteroids for DLE. Topical calcineurin inhibitors are useful for long-term therapy for lesions in areas of the skin where there is high risk for corticosteroid-induced atrophy (eg, face or intertriginous areas).</p><p></p><p class="bulletIndent2">Intralesional corticosteroid therapy may be beneficial for lesions that fail to improve with topical therapy but requires multiple injections and is most appropriate for the treatment of limited skin areas. (See <a class="local">'Limited disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extensive disease</strong> – For the initial treatment of most patients with extensive DLE or SCLE, we suggest systemic therapy with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> rather than other therapies  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Extensive disease or disease resistant to local therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rapidly progressing, severe disease</strong> – Rapid attainment of disease control is desirable for patients with disease that is progressing rapidly or is associated with cosmetically significant scarring or pigmentary alteration. For these patients, we suggest combining <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> treatment with a short course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> rather than hydroxychloroquine monotherapy or local therapy  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Aggressive disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of initial local treatment</strong> – Patients who fail initial treatments for DLE and SCLE may benefit from other interventions. When limited disease cannot be controlled with local therapy, we suggest proceeding to <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>  (<a class="graphic graphic_algorithm graphicRef78893" href="/d/graphic/78893.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with disease that does not respond to antimalarial treatment are candidates for other therapies. (See <a class="local">'Antimalarial drugs'</a> above and  <a class="medical medical_review" href="/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 2010; 19:1036.</a></li><li><a class="nounderline abstract_t">EPSTEIN JH, TUFFANELLI D, DUBOIS EL. LIGHT SENSITIVITY AND LUPUS ERYTHEMATOSUS. Arch Dermatol 1965; 91:483.</a></li><li><a class="nounderline abstract_t">Freeman RG, Knox JM, Owens DW. Cutaneous lesions of lupus erythematosus induced by monochromatic light. Arch Dermatol 1969; 100:677.</a></li><li><a class="nounderline abstract_t">Cripps DJ, Rankin J. Action spectra of lupus erythematosus and experimental immunofluorescence. Arch Dermatol 1973; 107:563.</a></li><li><a class="nounderline abstract_t">Hölzle E, Plewig G, Lehmann P. Photodermatoses--diagnostic procedures and their interpretation. Photodermatol 1987; 4:109.</a></li><li><a class="nounderline abstract_t">Wolska H, Błaszczyk M, Jabłońska S. Phototests in patients with various forms of lupus erythematosus. Int J Dermatol 1989; 28:98.</a></li><li><a class="nounderline abstract_t">van Weelden H, Velthuis PJ, Baart de la Faille H. Light-induced skin lesions in lupus erythematosus: photobiological studies. Arch Dermatol Res 1989; 281:470.</a></li><li><a class="nounderline abstract_t">Lehmann P, Hölzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181.</a></li><li><a class="nounderline abstract_t">Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006; 24:348.</a></li><li><a class="nounderline abstract_t">Hymes SR, Russell TJ, Jordon RE. The anti-Ro antibody system. Int J Dermatol 1986; 25:1.</a></li><li><a class="nounderline abstract_t">Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988; 31:1007.</a></li><li><a class="nounderline abstract_t">Herrero C, Bielsa I, Font J, et al. Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 1988; 19:1057.</a></li><li><a class="nounderline abstract_t">David KM, Thornton JC, Davis B, et al. Morbidity and mortality in patients with subacute cutaneous lupus erythematosus (SCLE) (abstract). J Invest Dermatol 1984; 82:408.</a></li><li><a class="nounderline abstract_t">Callen JP. Discoid lupus erythematosus--variants and clinical associations. Clin Dermatol 1985; 3:49.</a></li><li><a class="nounderline abstract_t">Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45:86.</a></li><li><a class="nounderline abstract_t">Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011; 64:37.</a></li><li><a class="nounderline abstract_t">Stege H, Budde MA, Grether-Beck S, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed 2000; 16:256.</a></li><li><a class="nounderline abstract_t">Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004; 50:3045.</a></li><li><a class="nounderline abstract_t">Callen JP, Roth DE, McGrath C, Dromgoole SH. Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus. Cutis 1991; 47:130.</a></li><li><a class="nounderline abstract_t">Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65.</a></li><li><a class="nounderline abstract_t">Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2017; 31:389.</a></li><li><a class="nounderline abstract_t">O'Kane D, McCourt C, Meggitt S, et al. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol 2021; 185:1112.</a></li><li><a class="nounderline abstract_t">Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301:93.</a></li><li><a class="nounderline abstract_t">DOEGLAS HM. CHRONIC DISCOID LUPUS ERYTHEMATOSUS TREATED WITH TRIAMCINOLONE AND PLASTIC OCCLUSION. Dermatologica 1964; 128:384.</a></li><li><a class="nounderline abstract_t">BJORNBERG A, HELLGREN L. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment. Br J Dermatol 1963; 75:156.</a></li><li><a class="nounderline abstract_t">Bjornberg A, Hellgren L. Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study. Indian J Dermatol 1966; 12:17.</a></li><li><a class="nounderline abstract_t">Mitchell AD, Mitchell DM. Fluocinolone acetonide in the treatment of chronic discoid lupus erythematosus. Lancet 1962; 280:359.</a></li><li><a class="nounderline abstract_t">Roenigk HH Jr, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980; 25:281.</a></li><li><a class="nounderline abstract_t">Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009; :CD002954.</a></li><li><a class="nounderline abstract_t">Böhm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003; 207:381.</a></li><li><a class="nounderline abstract_t">Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148:353.</a></li><li><a class="nounderline abstract_t">Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008; 64:337.</a></li><li><a class="nounderline abstract_t">Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65:54.</a></li><li><a class="nounderline abstract_t">Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009; 34:776.</a></li><li><a class="nounderline abstract_t">Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156:191.</a></li><li><a class="nounderline abstract_t">Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. J Med Assoc Thai 2012; 95:933.</a></li><li><a class="nounderline abstract_t">Barua DP, Chowdhury MIH, Mowla MR, et al. Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus. Dermatol Ther 2021; 34:e14675.</a></li><li><a class="nounderline abstract_t">Tlacuilo-Parra A, Guevara-Gutiérrez E, Gutiérrez-Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005; 44:1564.</a></li><li><a class="nounderline abstract_t">Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51:407.</a></li><li><a class="nounderline abstract_t">Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43:1383.</a></li><li><a class="nounderline abstract_t">Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002; 147:405.</a></li><li><a class="nounderline abstract_t">Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol 2010; 35:27.</a></li><li><a class="nounderline abstract_t">Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10:365.</a></li><li><a class="nounderline abstract_t">Knott HM, Martínez JD. Innovative management of lupus erythematosus. Dermatol Clin 2010; 28:489.</a></li><li><a class="nounderline abstract_t">Callen JP. Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16:245.</a></li><li><a class="nounderline abstract_t">Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118:412.</a></li><li><a class="nounderline abstract_t">Callen JP. Intralesional triamcinolone is effective for discoid lupus erythematosus of the palms and soles. J Rheumatol 1985; 12:630.</a></li><li><a class="nounderline abstract_t">Gunasekera V, Jayaram H, Kashani S, et al. Refractory discoid lupus erythematosis of the eyelid successfully treated with intra-lesional triamcinolone. Eye (Lond) 2008; 22:1205.</a></li><li><a class="nounderline abstract_t">Edwards AO. Central retinal artery occlusion following forehead injection with a corticosteroid suspension. Pediatr Dermatol 2008; 25:460.</a></li><li><a class="nounderline abstract_t">Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol Biopharm 1978; 16:395.</a></li><li><a class="nounderline abstract_t">McChesney EW, Rothfield NF. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7:328.</a></li><li class="breakAll">Callen JP, Camisa C. Antimalarial agents. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.259.</li><li><a class="nounderline abstract_t">Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.</a></li><li><a class="nounderline abstract_t">Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147:1261.</a></li><li><a class="nounderline abstract_t">Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 2009; 18:735.</a></li><li><a class="nounderline abstract_t">Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189:425.</a></li><li><a class="nounderline abstract_t">Lipsker D, Piette JC, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190:257.</a></li><li><a class="nounderline abstract_t">Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9:92.</a></li><li><a class="nounderline abstract_t">Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127:513.</a></li><li><a class="nounderline abstract_t">Yokogawa N, Eto H, Tanikawa A, et al. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis Rheumatol 2017; 69:791.</a></li><li><a class="nounderline abstract_t">Francès C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148:479.</a></li><li><a class="nounderline abstract_t">Sigges J, Biazar C, Landmann A, et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 2013; 12:694.</a></li><li><a class="nounderline abstract_t">Hesselvig JH, Egeberg A, Kofoed K, et al. Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. Br J Dermatol 2018; 179:1095.</a></li><li><a class="nounderline abstract_t">Drenkard C, Theis KA, Daugherty TT, et al. Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis. Lupus Sci Med 2022; 9.</a></li><li><a class="nounderline abstract_t">Achtman J, Kling MA, Feng R, et al. A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol 2016; 74:377.</a></li><li><a class="nounderline abstract_t">Boeckler P, Milea M, Meyer A, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005; 152:265.</a></li><li><a class="nounderline abstract_t">Miot HA, Bartoli Miot LD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005; 211:118.</a></li><li><a class="nounderline abstract_t">Gallego H, Crutchfield CE 3rd, Lewis EJ, Gallego HJ. Report of an association between discoid lupus erythematosus and smoking. Cutis 1999; 63:231.</a></li><li><a class="nounderline abstract_t">Koskenmies S, Järvinen TM, Onkamo P, et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus 2008; 17:337.</a></li><li><a class="nounderline abstract_t">Boeckler P, Cosnes A, Francès C, et al. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009; 145:1012.</a></li><li><a class="nounderline abstract_t">Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol 2015; 72:634.</a></li><li><a class="nounderline abstract_t">Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol 2011; 131:1981.</a></li><li><a class="nounderline abstract_t">Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148:317.</a></li><li><a class="nounderline abstract_t">Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11:71.</a></li><li><a class="nounderline abstract_t">Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008; 24:260.</a></li><li><a class="nounderline abstract_t">Heine G, Lahl A, Müller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010; 163:863.</a></li><li><a class="nounderline abstract_t">Cutillas-Marco E, Morales-Suárez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010; 19:810.</a></li><li><a class="nounderline abstract_t">Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5:114.</a></li><li><a class="nounderline abstract_t">Renne J, Werfel T, Wittmann M. High frequency of vitamin D deficiency among patients with cutaneous lupus erythematosus [corrected]. Br J Dermatol 2008; 159:485.</a></li><li><a class="nounderline abstract_t">Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991; 47:351.</a></li><li><a class="nounderline abstract_t">Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999; 41:1049.</a></li></ol></div><div id="topicVersionRevision">Topic 13772 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693197" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14275887" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : LIGHT SENSITIVITY AND LUPUS ERYTHEMATOSUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5365215" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cutaneous lesions of lupus erythematosus induced by monochromatic light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4572568" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Action spectra of lupus erythematosus and experimental immunofluorescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3658822" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Photodermatoses--diagnostic procedures and their interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2737817" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Phototests in patients with various forms of lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2610518" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Light-induced skin lesions in lupus erythematosus: photobiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179293" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966017" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lupus erythematosus: systemic and cutaneous manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3512458" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The anti-Ro antibody system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261587" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3060484" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Morbidity and mortality in patients with subacute cutaneous lupus erythematosus (SCLE) (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3880023" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Discoid lupus erythematosus--variants and clinical associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423840" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phototesting in lupus erythematosus: a 15-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167404" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11132128" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15457474" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of sunscreens to protect against ultraviolet-induced lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2001634" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797894" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27859683" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34170012" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797893" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Topical calcineurin inhibitors in cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14162995" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CHRONIC DISCOID LUPUS ERYTHEMATOSUS TREATED WITH TRIAMCINOLONE AND PLASTIC OCCLUSION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13971327" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5341750" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fluocinolone acetonide in the treatment of chronic discoid lupus erythematosus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6987043" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821298" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Drugs for discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657631" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588393" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18157526" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501887" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19456797" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17199600" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22919989" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33320408" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159951" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337984" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pimecrolimus 1% cream for cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266063" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174136" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549244" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824738" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cutaneous lupus erythematosus: issues in diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20510759" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Innovative management of lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12041952" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Management of skin disease in patients with lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7092253" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045868" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Intralesional triamcinolone is effective for discoid lupus erythematosus of the palms and soles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18188177" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Refractory discoid lupus erythematosis of the eyelid successfully treated with intra-lesional triamcinolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789088" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Central retinal artery occlusion following forehead injection with a corticosteroid suspension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/359493" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pharmacokinetics of antimalarials and proposals for dosage regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparative metabolic studies of chloroquine and hydroxychloroquine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparative metabolic studies of chloroquine and hydroxychloroquine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26992838" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768444" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19502270" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873836" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599397" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chloroquine-quinacrine association in resistant cutaneous lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787004" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1467292" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27992698" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508872" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23220353" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29885269" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35953237" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26775780" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15727637" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088157" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association between discoid lupus erythematosus and cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228753" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Report of an association between discoid lupus erythematosus and smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413417" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770440" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25648824" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734714" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105815" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of smoking in cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11958581" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18811868" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20662833" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305048" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431339" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Vitamin D deficiency in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503598" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : High frequency of vitamin D deficiency among patients with cutaneous lupus erythematosus [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2070657" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cutaneous lupus treated with topical tretinoin: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10570404" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of localized discoid lupus erythematosus with tazarotene.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
